AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows

Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ:AZN) , initially established in March 2025. • AZN is in positive territory. Get the market research here.Harbour BioMed is a biopharmaceutical company focused on the discovery and development of antibody therapeutics in immunology and oncology.The collaboration aims to discover and develop next-generation biotherapeutics, including antibody-drug conjugates and T cel ...